Imipenem/Cilastatin Atb

Imipenem, the active ingredient in Imipenem/Cilastatin Atb, is a carbapenem antibiotic presented as an intravenous formulation for injection use. It treats severe bacterial infections, including intra‑abdominal, urinary, skin, and central nervous system infections, in hospitalized adult patients.

GNH USA supplies Imipenem/Cilastatin Atb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Imipenem/Cilastatin is a broad‑spectrum carbapenem used for serious bacterial infections in the hospital setting.

Complicated intra‑abdominal infections: provides bactericidal activity against mixed aerobic and anaerobic pathogens to achieve clinical cure. Complicated urinary tract infections: eradicates resistant Gram‑negative organisms to resolve infection. Skin and soft tissue infections: targets resistant Staphylococcus and Gram‑negative bacteria for effective healing. Febrile neutropenia: offers rapid bacterial clearance in immunocompromised patients. Bacterial meningitis: penetrates the cerebrospinal fluid to treat susceptible meningitic pathogens.

Adverse reactions may occur with imipenem/cilastatin therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruptions. - Elevated liver enzymes: transient transaminase rise. - Headache: mild discomfort. - Injection site pain: local irritation.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment. - Anaphylaxis: severe allergic reaction requiring immediate care. - Clostridioides difficile‑associated diarrhea: possible colitis. - Thrombocytopenia: reduced platelet count. - Renal dysfunction: worsening kidney function. - Pseudomembranous colitis: rare but serious intestinal inflammation.

Before initiating therapy, consider patient‑specific factors and monitor for adverse events. - Renal function assessment: adjust dosing in patients with impaired clearance. - History of seizures: evaluate risk before use. - Allergy history: avoid in patients with known carbapenem hypersensitivity. - Concomitant valproic acid: monitor for reduced antiepileptic levels. - Pregnancy and lactation: weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Imipenem/cilastatin may interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Valproic acid: reduces plasma concentrations, risking seizure breakthrough. - CNS stimulants (e.g., quinidine, phenobarbital): increase seizure propensity. - Renal dehydropeptidase inhibitors: may alter cilastatin activity.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor renal function and electrolytes. - Aminoglycosides: increased risk of nephrotoxicity. - Warfarin: observe INR for possible anticoagulation changes.